Dr Eads on Nivolumab Plus Neoadjuvant Chemoradiation in Esophageal/GEJ Cancer

Jennifer R. Eads, MD, physician lead, GI Cancer Research, director, National Clinical Trials Network, Abramson Cancer Center, University of Pennsylvania, associate professor, clinical medicine (hematology-oncology), Penn Medicine, Perelman Center for Advanced Medicine, discusses the neoadjuvant pathologic complete response (pCR) rate results from the phase 2/3 ECOG-ACRIN EA2174 trial (NCT03604991) investigating the addition of nivolumab (Opdivo) to neoadjuvant chemotherapy and radiation in patients with locoregional esophageal and gastroesophageal junction (GEJ) adenocarcinoma.

Videos

Jennifer R. Eads, MD, discusses neoadjuvant pCR rates with the addition of nivolumab to neoadjuvant chemoradiation in esophageal/GEJ cancer.

Jennifer Eads, MD, assistant professor, senior clinical instructor, department of medicine, University Hospitals Cleveland Medical Center, discusses the classification of gastrointestinal (GI) neuroendocrine tumors (NETs).

The current classification scheme for GI NETs involves using the tumor histology, the Ki-67, and the mitotic index, as parameters for placing a tumor and guiding treatment, says Eads.

Pathological and clinical studies have indicated that the most important determinate of aggressiveness is the tumor differentiation status, Eads explains. This will place the patient’s tumor in the less aggressive or more aggressive G3 category. Patients with poorly-differentiated and higher Ki-67 tumors are placed in the higher category and don’t do as well, with a poor median overall survival of under a year. As for the well-differentiated category, these patients usually have a higher median overall survival and response to therapy, says Eads.

Jennifer Eads, MD, assistant professor, senior clinical instructor, department of medicine, University Hospitals Cleveland Medical Center, discusses the classification of gastrointestinal neuroendocrine tumors.
 

Jennifer Eads, MD

Articles

Dr Eads on Nivolumab Plus Neoadjuvant Chemoradiation in Esophageal/GEJ Cancer

Dr. Eads Discusses the Classification of Gastrointestinal NETs